Purpose: To evaluate the short-term efficacy and safety of recombinant human endostatin (Endostar) combined with chemoradiotherapy for the treatment of advanced, locally recurrent nasopharyngeal carcinoma (NPC).
Materials And Methods: Between March 2010 and October 2013, a total of 22 patients with stage rIII-IVb locally recurrent NPC underwent salvage radiotherapy with Endostar in Sun Yat-Sen University Cancer Center. Intensity-modulated radiotherapy (IMRT) was delivered. Platinum-based chemotherapy was used in a neoadjuvant protocol. Endostar was continuously administered intravenously (105 mg/m2) for 14 days (Days 1-14) from the first day of treatment during a 21-day cycle. Tumor response and treatment toxicities were observed.
Results: Until January 2014, the median follow-up time was 13 months (range, 4-41 months). All patients completed the planned radiotherapy. A complete response was achieved in 20 patients, and a partial response was achieved in 2 patients. The incidence of grade 3-5 late radiation injury in this study was 50% (11/22) and that of nasopharyngeal mucosal necrosis was 31.8% (7/22).
Conclusions: Endostar combined with chemoradiotherapy may be effective in decreasing both the incidence of nasopharyngeal mucosal necrosis. Studies with a larger sample size and longer follow-up are warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741813 | PMC |
| http://dx.doi.org/10.18632/oncotarget.5271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Combination therapy of envafolimab with endostar for advanced non-small cell lung cancer with low PD-L1 expression.
Front Oncol
November 2024
Department of Radiation Oncology, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.
In the management of advanced non-squamous non-small cell lung cancer (NSCLC) without driver gene mutations, the current therapeutic strategies encompass chemotherapy, chemotherapy combined with anti-angiogenic therapy, and chemotherapy combined with immunotherapy. For patients with high programmed death-ligand 1(PD-L1) expression, monotherapy with immune checkpoint inhibitors is a viable option. Recognizing that some patients cannot tolerate or decline chemotherapy, clinical practice has introduced non-chemotherapeutic treatment regimens, which have shown promising results.
View Article and Find Full Text PDFClinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma.
Front Med (Lausanne)
October 2024
Department of Radiotherapy, The Affiliated Chuzhou Hospital of Anhui Medical University, Chuzhou, China.
Objective: To evaluate the effectiveness and safety of concurrent chemoradiotherapy using Endostar continuous infusion for treating oesophageal squamous cell carcinoma (OSCC).
Method: A total of 62 patients with oesophageal carcinoma were divided into three groups: the Endostar continuous infusion group ( = 27), the Endostar intravenous drip group ( = 21) and the concurrent chemoradiotherapy group ( = 14). All patients underwent oesophageal radiotherapy (56-60 Gy) alongside concurrent chemotherapy (4 mg of raltitrexed +100 mg of oxaliplatin, two cycles).
β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer.
BMC Immunol
September 2024
Changzhou Medical Center, Nanjing Medical University, Changzhou, 213003, China.
Article Synopsis
- Immune checkpoint inhibitor rechallenge using β-glucan, Envafolimab, and Endostar shows promise for treating non-small cell lung cancer (NSCLC) patients who previously failed anti-PD-1 therapy.
- In a study with 23 participants, the overall response rate was 21.7%, and disease control rate reached 73.9%, with median progression-free survival of 4.3 months and overall survival of 9.8 months.
- Treatment-related adverse events occurred in over half of the patients (52.2%), with fatigue and hypothyroidism being the most common; however, no treatment-related deaths were reported.
Efficacy and Safety Analysis of Recombinant Human Endostatin (Endostar) Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer: A 2-Center Retrospective Study.
Technol Cancer Res Treat
July 2024
Department of Radiotherapy, ShuGuang Hospital, The Affiliated Hospital of Shanghai University of Chinese Traditional Medicine, Shanghai, China.
Background: This study aims to assess the efficacy and safety of Endostar in the management of locally advanced cervical cancer.
Methods: This retrospective, 2-center study enrolled 41 patients with locally advanced cervical cancer between June 2017 and December 2020. The patients were subjected to a combination of Endostar and chemoradiotherapy until they experienced disease progression or an unacceptable level of toxicity.
Effects of concurrent chemoradiotherapy with or without Endostar on the regression of retropharyngeal lymph node and prognosis of patients with locally advanced nasopharyngeal carcinoma: a retrospective study.
J Cancer Res Clin Oncol
May 2024
Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Background And Purpose: To investigate the effect of combining Endostar with concurrent chemoradiotherapy (ECCRT) compared to concurrent chemoradiotherapy (CCRT) on the regression rate of retropharyngeal lymph nodes (RLNs) and the relationship between regression rate of RLNs and prognosis of patients with locally advanced nasopharyngeal carcinoma (LANPC).
Methods: A total of 122 LANPC patients with RLNs metastasis were included. Metastatic RLNs were delineated both before and after treatment slice by slice on the magnetic resonance images cross-section.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!